Original paper
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
Abstract
Venetoclax is a BCL2 inhibitor approved for 17p-deleted relapsed/refractory chronic lymphocytic leukemia with activity following kinase inhibitors. We conducted a multicenter retrospective cohort analysis of patients with chronic lymphocytic leukemia treated with venetoclax to describe outcomes, toxicities, and treatment selection following venetoclax discontinuation. A total of 141 chronic lymphocytic leukemia patients were included (98%...
Paper Details
Title
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
Published Date
Jun 7, 2018
Journal
Volume
103
Issue
9
Pages
1511 - 1517